Regulus Therapeutics Inc. and its investors have more work to do before they can get preliminary approval for a $900,000 settlement to end a securities fraud lawsuit, a California federal judge said Dec. 20.
The biopharmaceutical firm’s investors accused it in 2017 of misleading them about the prospects of a new hepatitis C drug that purportedly increased patients’ risk of contracting jaundice.
The parties reached a settlement and asked the U.S. District Court for the Southern District of California for preliminary approval Dec. 12.
But the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.